CorMedix Inc. financial data

Symbol
CRMD on Nasdaq
Industry
Pharmaceutical Preparations
Location
300 Connell Drive, Suite 4200, Berkeley Heights, New Jersey
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 796 % -29.7%
Quick Ratio 0.28 % -91.6%
Debt-to-equity 14.7 % +38.2%
Return On Equity -77.2 % -31.8%
Return On Assets -67.3 % -27.1%
Operating Margin -46.8 K % -204%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 55 M shares +23.5%
Common Stock, Shares, Outstanding 55 M shares +23.5%
Entity Public Float 180 M USD +9.82%
Common Stock, Value, Issued 55 K USD +23.5%
Weighted Average Number of Shares Outstanding, Basic 57.5 M shares +30.4%
Weighted Average Number of Shares Outstanding, Diluted 57.5 M shares +30.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 65.4 K USD -65.7%
Cost of Revenue 819 K USD
Research and Development Expense 10.6 M USD -10.3%
Operating Income (Loss) -54.6 M USD -57.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -15.9 M USD -50.1%
Income Tax Expense (Benefit) -1.39 M USD
Net Income (Loss) Attributable to Parent -50.2 M USD -51.2%
Earnings Per Share, Basic -0.92 USD/shares -15%
Earnings Per Share, Diluted -0.92 USD/shares -15%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 35.2 M USD +39.2%
Inventory, Net 2.32 M USD
Assets, Current 63.4 M USD +11.7%
Property, Plant and Equipment, Net 1.91 M USD +18.5%
Operating Lease, Right-of-Use Asset 605 K USD -18.6%
Assets 68 M USD +14.8%
Accounts Payable, Current 2.83 M USD +95.4%
Employee-related Liabilities, Current 1.79 M USD +24.8%
Accrued Liabilities, Current 6.55 M USD +112%
Liabilities, Current 9.53 M USD +104%
Operating Lease, Liability, Noncurrent 477 K USD -24.5%
Liabilities 10 M USD +88.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax 83.5 K USD -17.6%
Retained Earnings (Accumulated Deficit) -336 M USD -17.6%
Stockholders' Equity Attributable to Parent 58 M USD +7.58%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 53.9 M USD -9.92%
Liabilities and Equity 68 M USD +14.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -17.3 M USD -66.5%
Net Cash Provided by (Used in) Financing Activities -97.1 K USD -101%
Net Cash Provided by (Used in) Investing Activities 8.94 M USD
Common Stock, Shares Authorized 160 M shares 0%
Common Stock, Shares, Issued 55 M shares +23.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -8.46 M USD +52.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 35.4 M USD +38.7%
Interest Paid, Excluding Capitalized Interest, Operating Activities 9.84 K USD +12.1%
Deferred Tax Assets, Valuation Allowance 70.8 M USD +22.5%
Deferred Tax Assets, Gross 70.8 M USD +22.5%
Operating Lease, Liability 632 K USD -17.9%
Depreciation 21.8 K USD +29.4%
Payments to Acquire Property, Plant, and Equipment 61.3 K USD +315%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -50.3 M USD -51.4%
Lessee, Operating Lease, Liability, to be Paid 742 K USD
Property, Plant and Equipment, Gross 1.87 M USD +15.9%
Operating Lease, Liability, Current 155 K USD +11.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 211 K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 208 K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 110 K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 169 K USD
Preferred Stock, Shares Issued 182 K shares 0%
Preferred Stock, Shares Authorized 2 M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 169 K USD
Operating Lease, Payments 51 K USD +2%
Additional Paid in Capital 394 M USD +16%
Preferred Stock, Shares Outstanding 182 K shares 0%
Share-based Payment Arrangement, Expense 68 K USD +36%
Interest Expense 35.4 K USD +18.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%